达卡他韦和索非布韦与联合利巴韦林治疗HCV感染疗效对比

摘要/Abstract

摘要： 目的评价达卡他韦和索非布韦对初治、经治HCV感染的疗效。方法选择2015年1月至2016年12月在我院就诊的慢性HCV感染患者268例,随机分为索非布韦和达卡他韦组(二联组)135例、索非布韦和达卡他韦联合利巴韦林组(三联组)133例,疗程24周,比较治疗24周的持续病毒学应答(SVR)和随访24周的复发比例,同时对比两组不良反应。结果两组治疗后SVR12(80.45%和85.94%)和SVR24(94.70%和96.03%)组间比较差异无统计学意义(P>0.05),以HCV基因型、IL28B基因型和既往治疗情况进行亚组分析,不同治疗方案的SVR24组间比较差异无统计学意义(P>0.05);随访12周和24周两组复发率分别为2.40%、0.83%和5.65%、4.20%,组间比较差异无统计学意义(P>0.05);最常见的不良反应为疲劳,发生率分别为17.04%和27.82%,两组不良反应发生率分别为27.41%和39.85%,组间比较差异有统计学意义(χ²=4.650,P=0.031)。结论达卡他韦和索非布韦对慢性HCV感染患者有较高的应答率,联合利巴韦林时应答率基本相当,但不良反应明显提高,不推荐利巴韦林联合DAA的治疗方案。

关键词: 达卡他韦, 索非布韦, 利巴韦林, 丙型肝炎, 应答率

鲍越. 达卡他韦和索非布韦与联合利巴韦林治疗HCV感染疗效对比[J]. 肝脏, 2018, 23(3): 232-235.

参考文献

[1] European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol, 2014, 60: 392-420.
[2] Bian DD, Zhou HY, Liu S, et al. Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals. Medicine (Baltimore), 2017, 96: e7885.
[3] Cunningham EB, Hajarizadeh B, Dalgard O, et al. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infect Dis, 2017, 17: 420.
[4] Lacombe K, Fontaine H, Dhiver C, et al. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. J Acquir Immune Defic Syndr, 2017, 75: 97-107.
[5] Poordad F, Lawitz E, Gutierrez JA, et al. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep, 2017, 5: 371-375.
[6] Pugi A, Bonaiuti R, Maggini V, et al. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database. Am J Health Syst Pharm, 2013, 70: 1039-1046.
[7] Liao H, Tan P, Zhu Z, et al. Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol, 2017, 41: 262-271.
[8] Sulkowski MS, Flamm S, Kayali Z, et al. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver Int, 2017, 37: 836-842.
[9] Alonso S, Riveiro-Barciela M, Fernandez I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat, 2017, 24: 304-311.
[10] Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology, 2012, 143: 608-618.
[11] Rafique G, Bukhsh A, Gul A, et al. Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy. Pak J Pharm Sci, 2017, 30: 11-16.
[12] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版). 肝脏,2015,20:933-1006.

[1]	庄焱, 卢捷, 谢青, 林兰意. 我国丙型肝炎肝硬化患者DAA治疗现状及短期预后的研究[J]. 肝脏, 2020, 25(3): 249-253.
[2]	张军建, 张矿召. 丙型肝炎病毒NS3非结构蛋白对人胚胎肝细胞L02细胞增殖以及端粒酶活性的研究[J]. 肝脏, 2020, 25(2): 135-137.
[3]	纪林秀, 吴亚, 王蜀强, 杨兴祥. 四川省丙型肝炎患者HCV基因分型及基线HCV NS5A耐药突变位点分析[J]. 肝脏, 2019, 24(8): 917-918.
[4]	谭文敏, 赖庭文, 韩锋. IL-28B基因多态性对直接抗病毒药物治疗慢性丙型肝炎患者疗效的预测价值[J]. 肝脏, 2019, 24(7): 776-779.
[5]	肖辉, 彭飞, 兰亚. 索非布韦联合利巴韦林治疗对丙型肝炎肝硬化患者肝功能及门静脉高压的影响[J]. 肝脏, 2019, 24(5): 547-549.
[6]	王丽, 陈竹, 曾义岚, 吴蓓, 周觅, 朱丽, 胡朝霞. 四川地区丙型肝炎病毒基因型分布特点[J]. 肝脏, 2019, 24(4): 450-451.
[7]	张咏芳, 杨俊梅. 慢性丙型肝炎患儿外周血NK细胞抑制受体的表达及其临床意义[J]. 肝脏, 2019, 24(4): 411-414.
[8]	蔡博, 刘晓丹, 王小青. IL-28B基因rs12979860基因多态性与慢性丙型肝炎转归的关系[J]. 肝脏, 2019, 24(11): 1299-1301.
[9]	吴建忠, 葛永亮. 多排螺旋CT评估慢性丙型肝炎患者肝纤维化的价值[J]. 肝脏, 2019, 24(11): 1295-1299.
[10]	卢捷, 陈立畅, 周惠娟, 谢青, 林兰意. 我国慢性丙型肝炎患者抗病毒治疗现状及药物选择策略分析[J]. 肝脏, 2019, 24(11): 1230-1233.
[11]	程文婷, 孔德华. 慢性丙型肝炎患者microRNA122水平与肝组织炎症坏死程度的关系[J]. 肝脏, 2019, 24(10): 1135-1137.
[12]	徐鹤翔, 郑吉顺, 解俊侠, 李明远, 章媛媛, 梁利民. 合肥地区丙型肝炎病毒基因分型分布特征[J]. 肝脏, 2019, 24(1): 81-83.
[13]	于建武, 李明荣, 张晓宇, 孙丽杰, 赵勇华, 刘伟. 糖脂代谢异常对丙型肝炎病毒感染肝细胞SIRT1-AMPK信号通路的影响[J]. 肝脏, 2019, 24(1): 28-30.
[14]	黄石珍, 段月勋, 汪习成, 杨环. 192例HIV合并HCV感染患者的联合抗病毒疗效分析[J]. 肝脏, 2018, 23(9): 785-788.
[15]	尹艳霞, 孟子强, 李晓光, 于建武, 李树臣, 许春海. 直接抗病毒药物治疗慢性丙型肝炎的临床疗效观察[J]. 肝脏, 2018, 23(9): 772-774.